It’s not easy to get depression-detecting AI through the FDA
Kintsugi shuts down after failing FDA approval.
Kintsugi, a startup focused on AI-driven detection of depression and anxiety through speech analysis, has shut down after failing to obtain FDA clearance in time. The company opted to open-source its technology, which could potentially be misused outside clinical settings, while highlighting the challenges of navigating the FDA's lengthy approval process for innovative AI solutions.
Key Takeaways
- 1.
Kintsugi's technology, aimed at detecting depression, is now open-sourced after the startup's closure.
- 2.
The FDA's approval process for AI devices can take years, complicating innovation.
- 3.
Concerns arise over the potential misuse of open-sourced mental health screening tools.
Get your personalized feed
Trace groups the biggest stories, videos, and discussions into one feed so you can stay current without scanning ten tabs.
Try Trace free